Providing Today's Patients with Medicines of the Future
Simcere Project X, only for “daring explorers”!
Simcere Zaiming, an innovative oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd., announced today that ...
On Aug. 26, 2023, SIM0278, an innovative interleukin 2 mutant fusion protein (IL-2 mu-Fc) independently developed by Simcere Pharmaceutical (2096. HK)...
On Aug. 23, 2023, Simcere Pharmaceutical Co., Ltd. (“Simcere”) and Lynk Pharmaceuticals (Hangzhou) Co., Ltd. ( “Lynk Pharmaceuticals”) announced posit...
On August 20, 2023, Simcere Zaiming Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Simcere pharmaceutical Group Ltd., ("Simcere Zaiming”)...
Staff
Current Brands of Products
Innovative Product Candidates
Covering Class III Hospitals
Covering Other Hospitals & Medical Institutions